Our Publications
We pride ourselves on making a meaningful contribution to the global quest to defeat cancer. Explore the publications and conference abstracts on this page to learn more about the research that supports our novel science.
Abstract
A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.
ASCO Gastrointestinal Cancers Symposium, Journal of Clinical Oncology 2022;40:4_suppl, TPS620-TPS620
A. Kasi, J. L. Iglesias.
Abstract
Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer
ASCO Annual Meetings 2020, Chicago (Abstract: Journal of Clinical Oncology 38, no. 15_suppl. DOI: 10.1200/JCO.2020.38.15_suppl.e16750
C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.)
Abstract
Pancreatic Tumor Remission in PDX-Models by Treatment with Gemcitabine in Combination with the Oxathiazine GP-2250 promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo. MBC Cancer
German Cancer Congress, February 2020, Berlin, Germany (Abstract: Oncology Res Treat 2020; 43 (supply 1): 1-265, abstract 455, page 58 DOI: 10.1159/000506491)
B. Majchrzak-Stiller, M. Buchholz, S. Hahn, C. Braumann, W. Uhl.
Publication
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.
2017, 17, 1-13. DOI: 10.1186/s12885-017-3204-x
M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik.
Abstract
Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo
German Cancer Congress, February 2016, Berlin, Germany (Abstract: Oncology Res Treat 2016; 39 (supply 1):1–175, abstract ID 0144, DOI: 10.1159/000444354)
M. Buchholz, B. Majchrzak-Stiller, S. Hahn, R.W. Pfirrmann, A.M. Chromik, W. Uhl.
Science
Discover our novel mechanism of action.
Our mechanism of action suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.